Maternal Vaccination Act

HR8024 (Maternal Vaccination Act) was introduced in the House on 2026-03-19 by Rep. Sewell (D-AL) and referred to the House Committee on Energy and Commerce. The bill amends the Public Health Service Act to add 'pregnant and postpartum individuals' to existing vaccination awareness campaigns and authorizes $17M annually for FY2027-2031 ($85M total). This is a pure authorization bill - no money has been appropriated, and the funding must go through subsequent appropriations bills. The $85M over 5 years is a rounding error compared to market caps. Pfizer ($26.69, down 4.99% in 30 days) has a market cap exceeding $150B. GSK ($52.21, down 5.4% in 30 days) is valued at ~$100B. Moderna's market cap is ~$30B. All three companies are experiencing downward price pressure unrelated to this bill - PFE and GSK have declined in April 2026 amid broader market conditions, not congressional actions. The bill does not mandate vaccine purchases, change ACIP recommendation criteria, alter Medicare/Medicaid reimbursement, or create any new procurement program. The mechanism is purely educational - CDC awareness campaigns that have historically shown modest, localized effects on vaccination rates. No specific vaccine manufacturer or product is named in the bill text. Legislative timeline: early stage with low momentum. A companion bill (S4132) exists in the Senate but also sits at the committee level. Identical bill HR8153 was also introduced, suggesting coordination. However, with only one House sponsor (junior member, not a committee chair) and no CBO score or committee markup scheduled, passage is uncertain in the current Congress.